News
Shipments will halt by close of business Tuesday evening, the company said. Sarepta had initially rejected the agency’s ...
Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...
The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...
Sarepta Therapeutics (SRPT) said late Monday it will pause all shipments of its Duchenne muscular dystrophy gene therapy, ...
After initially refusing to suspend Elevidys distribution after two deaths, Sarepta has now given in to the FDA’s request, ...
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand. | A brief skirmish between ...
Explore more
Sarepta will stop shipping its Duchenne muscular dystrophy gene therapy Elevidys following ongoing discussions with the FDA over safety labeling. The drugmaker said the pause, effective July 22, will ...
1d
Zacks Investment Research on MSNSRPT Down After Third Death in Muscular Dystrophy Gene Therapy ProgramShares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...
6h
NEWS10 ABC on MSNCornhole fundraiser raises over $5k for Muscular Dystrophy AssociationOn Sunday, a local family held their fourth annual Cornhole for a Cure fundraiser, raising money for the Muscular Dystrophy ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Earlier this week, we reported on a father of two children diagnosed with muscular dystrophy who has taken it upon himself to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results